KRAS Inhibition and the Tumor Microenvironment

Don’t miss our upcoming webinar to hear how Dr. Febe van Maldegem developed an Imaging Mass Cytometry workflow to phenotypically and spatially characterize remodeling of the lung tumor microenvironment following KRAS G12C inhibition. KRAS G12C is the driving oncogenic mutation in approximately 10% of all non-small cell lung cancer (NSCLC) patients and the first inhibitor of this mutation was recently approved for the treatment of locally advanced or metastatic NSCLC.

Spatial Characterization of the Lung Tumor Microenvironment in Response to KRAS G12C Inhibition

Speaker: Febe van Maldegem, PhD
The Francis Crick Institute, London
August 25, 2021
8 AM PDT | 11 AM EDT | 4 PM BST

Register Now